BOLDRINI, VALENTINA
BOLDRINI, VALENTINA
Medicina Sperimentale e Clinica
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm
2026 Bartalucci, Niccolò; Tarantino, Danilo; Loscocco, Giuseppe G.; Enderti, Alessio; Colazzo, Daniele; Santi, Raffaella; Parrini, Daniela; Balliu, Manjola; Boldrini, Valentina; Abbassi, Yasmine; Pelo, Elisabetta; Marchetti, Monia; Guglielmelli, Paola; Vannucchi, Alessandro M.
A safety evaluation of ruxolitinib for the treatment of polycythemia vera
2024 Boldrini, Valentina; Vannucchi, Alessandro M.; Guglielmelli, Paola
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis (RCO) Score in Primary Myelofibrosis
2025 Santi, Raffaella; Coltro, Giacomo; Di Stefano, Gioia; Atanasio, Alessandro; Cicogna, Paolo; Loscocco, Giuseppe G; Capecchi, Giulio; Boldrini, Valentina; Pescia, Carlo; Guglielmelli, Paola; Vannucchi, Alessandro M; Gianelli, Umberto
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry
2025 Guglielmelli, Paola; Ghirardi, Arianna; Carobbio, Alessandra; Masciulli, Arianna; Morrone, Lucrezia; Mora, Barbara; Rumi, Elisa; Triguero, Ana; Finazzi, Maria C.; Pettersson, Helna; Boldrini, Valentina; Vanni, Daniele; Rambaldi, Alessandro; Passamonti, Francesco; Alvarez‐Larràn, Alberto; Andreasson, Bjorn; Vannucchi, Alessandro M.; Barbui, Tiziano
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy
2023 Atanasio, A; Vanni, A; Maggi, L; Pilerci, S; Mazzoni, A; Capone, M; Crupi, F; Cicogna, P; Boldrini, V; Tekle, S; Colao, M G; Borella, M; Paoli, C; Rossolini, G M; Vannucchi, A M; Annunziato, F; Guglielmelli, P
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
2022 Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM
The Role and Impact of Non-driver Gene Mutations in Myelofibrosis
2026 Boldrini, Valentina; Guglielmelli, Paola; Vannucchi, Alessandro M.
Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers
2026 Boldrini, Valentina; Loscocco, Giuseppe G.; Guglielmelli, Paola; Gangat, Naseema; Vannucchi, Alessandro M.; Tefferi, Ayalew
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm | 2026 | Bartalucci, Niccolò; Tarantino, Danilo; Loscocco, Giuseppe G.; Enderti, Alessio; Colazzo, Daniele; Santi, Raffaella; Parrini, Daniela; Balliu, Manjola; Boldrini, Valentina; Abbassi, Yasmine; Pelo, Elisabetta; Marchetti, Monia; Guglielmelli, Paola; Vannucchi, Alessandro M. | |
| A safety evaluation of ruxolitinib for the treatment of polycythemia vera | 2024 | Boldrini, Valentina; Vannucchi, Alessandro M.; Guglielmelli, Paola | |
| Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis (RCO) Score in Primary Myelofibrosis | 2025 | Santi, Raffaella; Coltro, Giacomo; Di Stefano, Gioia; Atanasio, Alessandro; Cicogna, Paolo; Loscocco, Giuseppe G; Capecchi, Giulio; Boldrini, Valentina; Pescia, Carlo; Guglielmelli, Paola; Vannucchi, Alessandro M; Gianelli, Umberto | |
| Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry | 2025 | Guglielmelli, Paola; Ghirardi, Arianna; Carobbio, Alessandra; Masciulli, Arianna; Morrone, Lucrezia; Mora, Barbara; Rumi, Elisa; Triguero, Ana; Finazzi, Maria C.; Pettersson, Helna; Boldrini, Valentina; Vanni, Daniele; Rambaldi, Alessandro; Passamonti, Francesco; Alvarez‐Larràn, Alberto; Andreasson, Bjorn; Vannucchi, Alessandro M.; Barbui, Tiziano | |
| Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy | 2023 | Atanasio, A; Vanni, A; Maggi, L; Pilerci, S; Mazzoni, A; Capone, M; Crupi, F; Cicogna, P; Boldrini, V; Tekle, S; Colao, M G; Borella, M; Paoli, C; Rossolini, G M; Vannucchi, A M; Annunziato, F; Guglielmelli, P | |
| Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis | 2022 | Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM | |
| The Role and Impact of Non-driver Gene Mutations in Myelofibrosis | 2026 | Boldrini, Valentina; Guglielmelli, Paola; Vannucchi, Alessandro M. | |
| Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers | 2026 | Boldrini, Valentina; Loscocco, Giuseppe G.; Guglielmelli, Paola; Gangat, Naseema; Vannucchi, Alessandro M.; Tefferi, Ayalew |